Jointly constructed by Sinopharm Group and other Chinese enterprises, a hospital located in Guyana is officially put into use in July 2025. [Photo provided to chinadaily.com.cn]
Sinopharm Group, a centrally owned enterprise, has accelerated its international operations in recent years, now exporting products to over 70 countries and regions, with those involved in the Belt and Road Initiative being a focus for developing new markets, executives said last week.
In the vaccine area, one of the group's key business sectors, it has been actively promoting overseas production capacity collaborations and fast-tracking product approvals in key regions, the company executives said during a media interview.
"We have signed localization production agreements or intentions with companies in Indonesia, Myanmar, Brazil, Egypt, Morocco, Ghana, Saudi Arabia, and Hungary. These agreements cover products, including rotavirus, hepatitis B, influenza, and rabies vaccines," Liu Tun, deputy director of Sinopharm's public affairs department, said.
"Notably, the hepatitis B vaccine has already been locally packaged in Myanmar and approved for market by the country's drug regulatory authority," he said.
